10-Q
Quarterly Report
ALTO INGREDIENTS, INC.
ALTO
NASDAQ
CIK: 778164
File #: 000-21467
Balance Sheet
51 line items · 2 periods
XBRL
| Item | Mar 31, 2026 | Dec 31, 2025 |
|---|---|---|
Current Assets: | ||
Cash and cash equivalents | 20,309,000 | 23,415,000 |
Restricted cash | 1,334,000 | 2,258,000 |
Cash collateral balance | 1,334,000 | 2,258,000 |
Accounts receivable (net of allowance for credit losses of $61 and $76, respectively) | 59,700,000 | 55,069,000 |
Inventories | 52,831,000 | 61,676,000 |
Transferable tax credits, net | 11,530,000 | 7,500,000 |
Level 3 | 11,530,000 | 7,500,000 |
Derivative instruments | 7,831,000 | 525,000 |
Level 1 | 7,831,000 | 525,000 |
Commodity contracts | 7,831,000 | 525,000 |
Other current assets | 5,017,000 | 5,474,000 |
Total current assets | 158,552,000 | 155,917,000 |
Property and equipment, net | 193,199,000 | 198,501,000 |
Other Assets: | ||
Right of use operating lease assets, net | 17,215,000 | 16,931,000 |
Intangible assets, net | 7,419,000 | 7,574,000 |
Other assets | 9,908,000 | 9,863,000 |
Total other assets | 34,542,000 | 34,368,000 |
Total Assets | 386,293,000 | 388,786,000 |
Corporate and other | 22,970,000 | 32,797,000 |
Western production | 44,033,000 | 43,131,000 |
Marketing and distribution | 104,407,000 | 103,911,000 |
Pekin Campus Production | 214,883,000 | 208,947,000 |
Current Liabilities: | ||
Accounts payable | 19,303,000 | 14,509,000 |
Accrued liabilities | 12,332,000 | 16,691,000 |
Current portion – long-term debt | — | 16,600,000 |
Current portion – operating leases | 4,975,000 | 4,958,000 |
Derivative instruments | 301,000 | 1,067,000 |
Level 1 | 301,000 | 1,067,000 |
Commodity contracts | 301,000 | 1,067,000 |
Other current liabilities | 4,741,000 | 5,246,000 |
Total current liabilities | 41,652,000 | 59,071,000 |
Long-term debt | 73,056,000 | 63,027,000 |
Operating leases, net of current portion | 13,240,000 | 13,012,000 |
Other liabilities | 8,467,000 | 8,435,000 |
Total Liabilities | 136,415,000 | 143,545,000 |
Stockholders’ Equity: | ||
Preferred stock, $0.001 par value; 10,000 shares authorized; Series A: 1,684 shares authorized; no shares issued and outstanding as of March 31, 2026 and December 31, 2025; Series B: 1,581 shares authorized; 927 shares issued and outstanding as of March 31, 2026 and December 31, 2025; liquidation preference of $18,075 as of March 31, 2026 | 1,000 | 1,000 |
Common stock, value | 78,000 | 77,000 |
Additional paid-in capital | 1,052,472,000 | 1,051,795,000 |
Accumulated other comprehensive income | 5,461,000 | 5,461,000 |
Accumulated deficit | (808,134,000) | (812,093,000) |
Total Stockholders’ Equity | 249,878,000 | 245,241,000 |
Accumulated Other Comprehensive Income | 5,461,000 | 5,461,000 |
Accumulated Deficit | (808,134,000) | (812,093,000) |
Additional Paid-In Capital | 1,052,472,000 | 1,051,795,000 |
Common Stock | 78,000 | 77,000 |
Preferred Stock | 1,000 | 1,000 |
Total Liabilities and Stockholders’ Equity | 386,293,000 | 388,786,000 |